Decentralized Clinical Trial Solution

Pharmaceutical companies leave no stone unturned in ensuring continuity of ongoing clinical trials, as they are expensive, complicated, highly regulated and take years for completion. Despite the need to develop effective new treatments, less than 5% of eligible patients participate in clinical research a situation even more pronounced for racial and ethnic minorities. Up to 20% of clinical trials are either terminated early for failing to meet recruitment targets or are completed while failing to meet the original target. (Noah Goodson, 2022)

The traditional clinical trial methodology was also based on the premise that patients or trial subjects need to be present in-person at the site to ensure safety, compliance and integrity. However with the restrictions enforced during the pandemic, sponsors had to identify alternate methods of timely and safe deliverance of medicines while also ensuring data integrity and ensuring continuity of care.

COVID-19 pandemic tested this hypothesis as sponsors dealt with challenges not only like safely and timely deliverance of medicines and treatments to trial subjects due to supply chain issues but also preserving the continuity of care and ensuring data integrity.